Fig. 3.

The therapy stage of TET against ASFV infection on PAMs. (A) The TOA assay was divided into pre-treatment, co-treatment and after-treatment stages. And pre-treatment stage means before ASFV was added, co-treatment stage and after-treatment stage meant after ASFV was added. (B) The experiments were performed following Fig. 3A, and qRT-PCR assay was performed. (C) The experiments were performed following Fig. 3A, and Western Blot assay was performed. (D) qRT-PCR analysis of the TET-pretreated-ASFV infection on PAMs. (E) The mRNA level of CD1d was examined by qRT-PCR. (F) qRT-PCR assay was used to determine whether CD1d was the target of TET. ****P < 0.0001, ***P < 0.001.